Beyond Awareness: From Screening to Cure - A Strategic Direction for Sarawak

February is a significant month for the global medical community. World Cancer Day and World Rare Disease Day remind us not only of the scale of human suffering, but also of the responsibility to move beyond awareness toward durable solutions.

At the Sarawak Society for Cell and Gene Therapy Research (SSCTR), we believe the conversation must now shift. For decades, many patients have lived with lifelong symptom management. Today, advances in cell and gene therapy allow us to realistically discuss cure.

From Treatment to Immune Re-engineering

In oncology, cell therapy has become a transformative pillar of care. Technologies such as CAR-T cell therapy demonstrate what is possible when we harness and re-engineer a patient’s own immune system to recognize and eliminate malignant cells. The clinical success seen in certain leukemias and lymphomas represents more than scientific progress. It signals a structural shift in how we approach previously refractory cancers.

This is no longer theoretical medicine. It is applied science with measurable outcomes.

Rare Diseases: Screening Is Necessary but Not Sufficient

Rare diseases remain a major yet under-recognized burden. Globally, they affect up to 5.9% of the population. In Malaysia, a rare disease is defined as affecting fewer than 1 in 4,000 individuals. The Ministry of Health’s National Framework for Rare Diseases (2020 - 2030) has appropriately emphasized structured national response.

The National Thalassemia Screening Programme illustrates the value of early detection. Since 2016, more than 58,000 Form Four students have been identified as carriers. Screening allows for informed family planning, genetic counseling, and long-term healthcare planning.

However, screening only maps the challenge.

For patients already living with transfusion-dependent Thalassemia, especially students, the disease continues to shape daily life. Hospital visits every three to four weeks disrupt schooling, cause chronic fatigue, and limit academic and social development. We must acknowledge that surveillance alone does not restore quality of life.

The Strategic Case for Local Cell and Gene Therapy

Cell and Gene Therapy (CGT) offers a fundamentally different paradigm. Instead of managing symptoms indefinitely, autologous approaches enable correction of a patient’s own stem cells. For conditions such as Thalassemia, this holds the potential for transfusion independence.

The question before us is not whether the science works. It is whether we are prepared to build the systems required to deliver it locally.

Cost remains a major barrier. Imported advanced therapies are often priced beyond the reach of public health systems. For Sarawak, decentralization may be the more strategic path forward.

The “Place-of-Care” manufacturing model, as promoted internationally by organizations such as Caring Cross, proposes hospital-based, decentralized manufacturing ecosystems. Under such frameworks, treatment production is embedded within clinical settings, reducing logistical complexity and potentially lowering cost.

For Sarawak, this model aligns with our geographic realities and healthcare structure. It also supports capacity building, local expertise development, and long-term sustainability.

From Awareness to Capability

As a society, SSCTR’s role is not merely to advocate for technology adoption. It is to advocate for responsible integration, ensuring ethics, regulatory compliance, workforce readiness, and equitable access.

Genetic screening provides the roadmap. Localized CGT provides the intervention. Together, they form a coherent strategy.

Our responsibility is to ensure that a diagnosis of cancer or rare disease in Sarawak does not automatically translate into lifelong limitation.

Awareness begins the conversation. Capability completes it.

Dr. Samuel Ting

President

Sarawak Society for Cell and Gene Therapy Research